Article
TROP2 expression is associated with early stage and favorable prognosis in Upper tract urothelial carcinoma
2025-11-06
Abstract excerpt
<title>Abstract</title> <p> <bold>Background:</bold> TROP2 has recently emerged as a promising therapeutic target, with the antibody‒drug conjugate sacituzumab govitecan. Nevertheless, its biological and clinical relevance in urothelial carcinoma (UC) has not been fully investigated. <bold>Methods</bold> : We evaluated TROP2 protein expression in 114 upper tract UC (UTUC) tissue samples using immunohistochemi...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 05a15c9b-de99-58a9-9694-c028d36c3b94
- DOI
- 10.21203/rs.3.rs-7734563/v1
